Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Cancer Drug Resistance Année : 2022

Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma

Résumé

Sarcomas are a large family of cancers originating in the mesenchyme. Composed of more than 100 histological subtypes, soft tissue and bone sarcomas remain clinically challenging, particularly in children and adolescents in whom sarcomas are the second most common malignant entities. Osteosarcoma is the main primary bone tumor in adolescents and young adults, and is characterized by a high propensity to induce distant metastatic foci and to become multi-drug resistant. The innate and acquired resistance of osteosarcoma can be explained by high histological heterogeneity and genetic/molecular diversity. In the last decade, the notion of cancer stem-like cells (CSCs) has emerged. This subset of cancer cells has been linked to drug resistance properties, recurrence of the disease, and finally therapeutic failure. Although CSCs remain controversial, many elements are in favor of them playing a role in the development of the drug resistance profile. The present review gives a brief overview of the most recent biological evidence of the presence of CSCs in osteosarcomas and their role in the drug resistance profile of these rare oncological entities. Their use as promising therapeutic targets will be discussed.
Fichier principal
Vignette du fichier
Jubelin et al Current Drug Resistance REV1unmarked.pdf (697.49 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

inserm-03550410 , version 1 (01-02-2022)

Identifiants

Citer

Camille Jubelin, Javier Munoz-Garcia, Denis Cochonneau, Emilie Moranton, Marie Françoise Heymann, et al.. Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma. Cancer Drug Resistance, 2022, 5, ⟨10.20517/cdr.2021.130⟩. ⟨inserm-03550410⟩
48 Consultations
71 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More